At the American Society of Clinical Oncology Genitourinary Cancer Symposium, Karen Hoffman, MD, MHSc, MPH, University of Texas MD Anderson Cancer Center, and Christopher Wallis, MD, PhD, FRCSC, University of Toronto, discuss the updated patient-level data of the FORMULA-509 trial, showing that abiraterone acetate plus prednisone and apalutamide improve prostate cancer outcomes without causing a detectable difference in patient-reported hormonal function, fatigue, or mental status.
Dr. Karen Hoffman on Patient-Reported HRQoL in FORMULA-509
By Karen Hoffman, MD, MHSc, MPH, Christopher Wallis, MD, PhD, FRCSC - Last Updated: January 30, 2024Related Posts
Dr. Calais explains the utility of PSMA PET prior to RT for unfavorable intermediate-risk or high-risk prostate cancer.
Dr. Saby George continues with the survival implications and ramifications from the CheckMate 214 long-term data.
Dr. Saby George provides details on CheckMate 67T for the utility of subcutaneous nivolumab for advanced or metastatic ccRCC.
Dr. Powles offers his thoughts on the latest OS data from EV-302 for patient subgroups and immune-related toxicity.
Dr. Powles gives his unique feedback on what to make of KEYNOTE-564 and how aRCC frontline options should be compared.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.